Lexaria Bioscience Corp. LEXX Archives - Page 30 of 39

TuesdayMar 08, 2022 3:02 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Award for Oral Nicotine Compound Patent

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has been granted an Australian patent titled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof.” The patent expands Lexaria’s world patent portfolio to 24. According to the announcement, the patent expands the company’s international intellectual property rights to apply its proprietary DehydraTECH(TM) enhancement technology to most oral forms of nicotine delivery, which would include pills, tablets, lozenges, capsules, pouches, gums and sprays. In addition to covering different forms of delivery, the patent also includes an array of nicotine forms, such as free base nicotine, nicotine salts, polymer resins of nicotine…

FridayMar 04, 2022 9:15 am

Studies Advance Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology for Significantly Improving Pharmaceutical Drugs

Lexaria Bioscience is dedicated to applying its patented technology to pharmaceutical drug offerings to enhance their performance and speed their rate of effective use The company’s flagship DehydraTECH(TM) technology has delivered numerous successes in studies of its potential for treating high blood pressure and heart disease, nicotine addiction, and virus infection Most recently, the company reported successes in increasing the speed and effectiveness in a drug treating erectile dysfunction (“ED”) in laboratory animals Lexaria is preparing an investigational new drug (“IND”) application for its hypertension line of study with the aim of achieving a new drug application (“NDA”) approval from…

ThursdayMar 03, 2022 2:40 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Faster, Higher Overall Delivery of Sildenafil into Bloodstream

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently released positive results from an animal study that evaluated DehydraTECH(TM) processing of the phosphodiesterase inhibitor (“PDE5 inhibitor”) sildenafil as potential use in the management of erectile dysfunction. “A clear trend emerged during the course of the study – a faster and higher overall delivery of sildenafil into the bloodstream. During the animal study, it was determined that in as little as four minutes of dosing, the DehydraTECH formulation of sildenafil delivered 74% more of the PDE5 inhibitor into the bloodstream on average than the concentration-matched, generic control formulation. Within seven minutes, the DehydraTECH-sildenafil formulation…

MondayFeb 28, 2022 9:15 am

As It Targets Multiple Large Market Opportunities, Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Leveraging Elaborate Studies to Progressively Remove Risks Associated with Commercialization, Regulation

Leveraging the versatility and benefits of its DehydraTECH(TM) technology, Lexaria is targeting multiple large market opportunities as it attempts to ensure it has multiple paths to success The technology aims to help companies offering oral drugs, supplements, and nicotine formulations to improve the effectiveness of their existing or planned products Lexaria has undertaken various studies whose findings show the benefits of DehydraTECH-processed products relative to controls The company intends to use the positive results from its studies to incrementally remove risks associated with commercialization and regulation Lexaria Bioscience (NASDAQ: LEXX), a global drug delivery technology company transforming existing consumer products…

FridayFeb 25, 2022 1:32 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic of Positive Study Results, Eyes ‘Most Exciting Year Ever’

Lexaria Bioscience Corp. (NASDAQ: LEXX) achieved myriad milestones in 2021, with CEO Chris Bunka noting in an annual letter to shareholders that January 2021 marked the birth of a modern version of the company. A recent article contains excerpts from the letter, in which Bunka writes, “During 2021, we completed research & development (‘R&D’) and validating work equal to or greater than all the combined amount previously completed since 2018! We have conducted studies across broad areas of interest but also concentrated in specific areas where we have supportive data,” In 2021, Lexaria’s most significant area of investigation was DehydraTECH(TM)-processed…

WednesdayFeb 23, 2022 10:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About its Expanded DehydraTECH Investigations; Plans for More Studies in 2022

Lexaria just announced ground-breaking findings from its recently-concluded Sildenafil animal study The success of this study sets the stage for various other studies on the use of the company’s patented DehydraTECH technology The company is set to commence dosing its most extensive hypertension study in April 2022, with results expected in Q3 2022 Its successful completion could greatly enhance Lexaria’s leadership position in the global drug delivery market Lexaria Bioscience (NASDAQ: LEXX) kicked off the 2022 calendar year by receiving independent review board approval for its upcoming DehydraTECH(TM)-CBD human hypertension study, HYPER-H21-4. Additionally, in what marks another critical milestone, the…

FridayFeb 18, 2022 1:55 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Is World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Technology

Lexaria Bioscience Corp. (NASDAQ: LEXX) commented on an independent study headed by lead research scientist Dr. Richard van Breeman, which discovered that cannabinoids can block cellular entry of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its emerging variants. The study showed that smoking and vaping are likely ineffective measures, whereas oral delivery methods are. “As a company, Lexaria is already actively exploring and researching DehydraTECH(TM)-enabled cannabinoid formulations across various potential therapeutic applications, including oral formulations that are being prepared for registered clinical trials as a possible new pharmaceutical product,” reads a recent article. “In response to the study, Chris…

WednesdayFeb 16, 2022 11:13 am

Following Successful Sildenafil Animal Study, Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Plans for More Studies in 2022

Lexaria’s animal study could be the first step to developing faster and better acting sildenafil oral formulations The most prominent study for Lexaria in 2022 is HYPER-H21-4, investigating patented DehydraTECH(TM)-CBD for hypertension and heart disease Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced positive findings in an animal study that evaluated DehydraTECH(TM) processing of the phosphodiesterase inhibitor (PDE5 inhibitor) sildenafil as potential use for erectile dysfunction management. A clear trend emerged during the course of the study – a faster and higher overall delivery of sildenafil into the bloodstream (https://ibn.fm/oU4wW). During the animal study, it…

FridayFeb 11, 2022 1:09 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated for Potential Treatment Options for Multiple Conditions

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Chris Bunka noted that Lexaria would continue to see significant milestones in utilizing its patented DehydraTECH drug delivery technology in 2022. “Calendar 2022 will continue to see significant milestones utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking… We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease and diabetes,” a recent article quotes Bunka as saying. Lexaria received independent review board approval, marking…

FridayFeb 11, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Shows Promise in Improving Performance, Speed of ED Drugs

Health and wellness drug bio-effectiveness innovator Lexaria Bioscience is advancing human testing of its patented DehydraTECH(TM) technology for the potential treatment of high blood pressure and heart disease Lexaria also recently announced that DehydraTECH boosted the speed and effectiveness of sildenafil in laboratory rats for the potential treatment of erectile dysfunction (“ED”) The company’s statement notes that DehydraTECH-processed sildenafil “delivered 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation” ED affects some 30 million men in the United States and is expected to affect about 322 million men worldwide by 2025 Lexaria Bioscience (NASDAQ: LEXX),…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX